151509-27-2

Usage

Uses

Used in Pharmaceutical Industry:
2'-Ac-Docetaxel is used as an anticancer agent for its potential to treat various types of cancers. The acetyl modification at the 2' position is intended to improve the drug's solubility and stability, which may lead to enhanced bioavailability and therapeutic efficacy. Additionally, the reduced toxicity compared to the original docetaxel could result in fewer side effects for patients undergoing cancer treatment.
Used in Cancer Research:
In the field of cancer research, 2'-Ac-Docetaxel is utilized for studying its potential to offer improved therapeutic effects over the standard docetaxel. Researchers are investigating its mechanism of action, pharmacokinetics, and pharmacodynamics to understand how the acetyl group modification influences the drug's interaction with cancer cells and its overall effectiveness in treating malignancies.
Used in Drug Formulation Development:
2'-Ac-Docetaxel is also used in the development of novel drug formulations to enhance the delivery and bioavailability of the compound. The improved solubility and stability of 2'-Ac-Docetaxel can facilitate the creation of more effective dosage forms, such as nanoparticles or liposomes, which can target cancer cells more precisely and minimize damage to healthy tissues.

Upstream product

• 1227402-72-3 N'-Boc-2'-acetyldocetaxel 
• 24424-99-5 di-tert-butyl dicarbonate 
• 132201-32-2 (2R,3S)-3-phenylisoserine hydrochloride 
• 145514-62-1 RPR 130523 
• 1219592-76-3 (2R,3S)-N-Boc-3-phenylisoserine benzyl ester 
• 1219592-92-3 (2R,3S)-N-Boc-2-acetyl-3-phenylisoserine benzyl ester 
• 1219592-93-4 (2R,3S)-N,N-di-Boc-2-acetyl-3-phenylisoserine benzyl ester 
• 1219592-94-5 (2R,3S)-N,N-di-Boc-2-acetyl-3-phenylisoserine 
• 1227402-71-2 7,10-di-troc-N'-Boc-2'-acetyldocetaxel 
• 1056998-48-1 C₅₅H₇₁NO₁₉ 
• 108-24-7 acetic anhydride 
• 114915-20-7 Docetaxel 

Downstream Products

• 114915-20-7 Docetaxel 

Relevant academic research and scientific papers

Conformation of Taxotere and analogues determined by NMR spectroscopy and molecular modeling studies

Taxol 1 and Taxotere 2 are antitumor compounds interacting with tubulin proteins. In order to find the best conformational fit to the receptor site, the structures of taxotere and twelve analogues showing various in vitro biological activity on tubulin, have been investigated by 1H NMR spectroscopy and molecular modeling studies. These structures were compared to that of Taxotere 2 obtained by X-ray analysis. The results obtained from these studies suggest that the most active 2′R,3′S compounds possess a conformation in which the benzoate group at C-2 holds the side chain in a defined position due to hydrophobic interactions between this group and the N-amido or N-carbonyloxy group at C-3′. This situation together with the presence of hydrogen bonding between 2′OH-3′NH and 2′OH-1′C - O gives rise to a specific orientation of the hydroxyl and phenyl groups at C-2′ and C-3′. On the other hand, the 2′S,3′R isomers which display low in vitro biological activity (ie: on tubulin), such as isotaxotere 8, possess a different conformation with no hydrophobic interactions between the side chain and the taxan skeleton.

An efficient semi-synthetic method to construct docetaxel via sterically crowded linear side chain esterification

An efficient semi-synthetic method was developed to construct docetaxel 1 by using N,N-di-Boc protected linear isoserine derivative 5 as the side chain source, in which, bulky protecting group on the nitrogen atom blocked C-2′ position and prohibited unav

METHOD FOR PREPARING TAXANE DERIVATIVES

Provided is a method for preparing a taxane derivative, comprising: carrying out condensation of a phenylisoserine derivatives having a protective group introduced thereto or a mixture of isomers thereof, as a side chain, with a baccatin III derivative or 10-deacetyl-baccatin III derivative to obtain a mixture of isomers; separating the isomers via chromatography; and carrying out a reversion of the stereochemical structure of a selectively separated isomer, which is suitable for producing a taxane derivative in a large scale with high yield.

PROCESS FOR THE PREPARATION OF DOCETAXEL, ITS INTERMEDIATES, AND METHODS FOR PREPARATION THEREOF

The present invention disclosed an process for preparing docetaxel 1, including the following steps: a) hydroxyl acylation reaction of compound 2 and 3 to obtain compound 4; b) deprotection group R1 of the hydroxyl group of compound 4 obtained

METHOD FOR PREPARING TAXANE DERIVATIVES

Provided is a method for preparing a taxane derivative, comprising: carrying out condensation of a phenylisoserine derivatives having a protective group introduced thereto or a mixture of isomers thereof, as a side chain, with a baccatin III derivative or 10-deacetyl-baccatin III derivative to obtain a mixture of isomers; separating the isomers via chromatography; and carrying out a selective reversion of the stereochemical structure of a separated isomer, which is suitable for producing a taxane derivative in a large scale with high yield.

ONE POT SYNTHESIS OF TAXANE DERIVATIVES AND THEIR CONVERSION TO PACLITAXEL AND DOCETAXEL

A process is provided for the semi-synthesis of taxane intermediates useful in the preparation of paclitaxel and docetaxel, in particular, the semi-synthesis of protected taxane intermediate in a one pot reaction, of protecting the C-10 and attaching a si